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Abstract
Background: Hepatitis C infection (HCV) among individuals aged 15–24 years has increased in Massachusetts, likely
due to injection drug use. The prevalence of injection equipment sharing (sharing) and its association with age was
examined in a cohort of out-of-treatment Massachusetts substance users.
Methods: This analysis included baseline data from a behavioral intervention with substance users. Younger and
older (<25 versus ≥25 years) injection drug users were compared on demographic characteristics, substance use
practices, including factors present during the most recent sharing event (“event-level factors”), and HCV testing
history.
Results: Sharing was reported by 41% of the 484 individuals who reported injection drug use in the past 30 days.
Prevalence of sharing varied by age (50% <25 years old versus 38% ≥25 years, p = 0.02). In a multivariable logistic
regression model younger versus older individuals had twice the odds of sharing (95% CI= 1.26, 3.19). During their
most recent sharing event, fewer younger individuals than older had their own drugs available (50% versus 75%,
p< 0.001); other injection event-level factors did not vary by age. In the presence of PTSD, history of exchanging
sex for money, or not being US born, prevalence of sharing by older users was higher and was similar to that of
younger users, such that there was no association between age and sharing.
Conclusions: In this cohort of injection drug users, younger age was associated with higher prevalence of sharing,
but only in the absence of certain stressors. Harm reduction efforts might benefit from intervening on mental
health and other stressors in addition to substance use. Study findings suggest a particular need to address the
dangers of sharing with young individuals initiating injection drug use.
Keywords: Injection drug use, Injection equipment sharing, Young age, Hepatitis C
Background
A recent Morbidity and Mortality Weekly Report (MMWR)
found that, between 2002 and 2009, the rate of hepatitis
C (HCV) infection increased statewide among young
people (15–24 years of age) in Massachusetts, primarily
among non-Hispanic whites. The investigators identi-
fied injection drug use as the primary risk factor for
HCV infection in this population of adolescents and
young adults, with heroin being the primary drug of
injection [1]. During this same time period there was
also an apparent increase in heroin use among young
people in Massachusetts and other states [2].
In light of these recent findings, it is important to under-
stand the connection between age and injection drug use
and sharing of injection drug use equipment in particular.
Shared use of injection drug equipment (sharing) is a
strong risk factor for HCV infection [3]. While a few stud-
ies of injection drug users have found either no association
with age and sharing [4,5] or have found that older age is
a risk factor [6], most studies have reported that younger
injection drug users are more likely than older users to
share needles or other drug equipment [7-13]. The rea-
sons for the observed association between younger age
and sharing are multifactorial. New initiates into injection
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require help from others [14]; they also may have not been
adequately exposed to prevention messages about the risks
of sharing [15]. Additionally, young users may learn to in-
ject in the context of strong social networks that encour-
age sharing and where trust and friendship make sharing
more comfortable and less risky [16]. What has not been
previously explored is whether this association between
younger age and sharing holds steady across all cohorts of
injection drug users or whether there are factors that
might modify this association, as is suggested by the seem-
ingly contradictory findings mentioned above.
The overall objective of this study was to further the
understanding of why younger individuals are often
more likely to share injection drug equipment, and to
identify factors that might modify this association. Toward
t h i se n dw ee x a m i n e dd a t af r o mac o h o r to fG r e a t e r
Boston area injection drug users followed during the
period in which HCV infection in Massachusetts was
observed to increase. Our primary aims were to: (1) de-
scribe demographic and drug use practices overall and
by age (<25/≥25 years, to correspond to the upper age
for which HCV infection was observed to increase in
Massachusetts); (2) estimate the association between
age and sharing, adjusting for other risk factors of sharing;
(3) compare younger (<25 years) and older (≥25 years) in-
dividuals on factors present at their most recent sharing
injection event; (4) explore whether the association be-
tween age and sharing varies between levels of factors
indicative of personal stressors or social instability, in-
cluding exchange of sex for money, post-traumatic
stress disorder (PTSD) symptoms, and whether US born;
and (5) summarize the self-reported HCV testing history
and the HIV prevalence of injection drug users in the co-
hort, overall, by age group, and by sharing status.
Methods
Study sample
The parent study from which this analysis is drawn was a
randomized controlled trial of a behavioral intervention to
reduce sexual risk behaviors among hospital patients who
reported drug use within the past 30 days. An ethnically
diverse population of patients registered for medical care
from November 2004 through May 2008 was screened for
eligibility at an academic, urban, level-I, trauma center
emergency department using a Health Needs History
screening survey [17]. Eligibility criteria for the parent
study included current (past 30-day) cocaine or heroin
use, English or Spanish speaking, ages 18–54 years, and a
Drug Abuse Severity Test Score ≥3 indicating moderate or
higher severity [18]. In the current analysis, we included
all enrollees from the parent study who reported injection
drug use at the baseline visit. The study was approved by
the Boston University Medical Campus Institutional
Review Board, and written informed consent was obtained
for all enrollees. A National Institutes of Health Certificate
of Confidentiality was obtained to protect subject data
from subpoena. Details of the enrollment process and
intervention are described elsewhere [19].
Study design and laboratory procedures
The present study is a cross-sectional analysis that used
data collected at the baseline visit of the intervention
study. Enrolled participants were interviewed face-to-face
by trained research assistants for demographic charac-
teristics, health status, drug use patterns, sexual practices,
HCV testing history, and PTSD symptoms using the
PTSD Checklist-Civilian Version (PCL-C) [20]. Testing
for HIV infection was conducted using oral mucosal tran-
sudate (OMT) samples (OraQuick®, Orasure Technolo-
gies, Inc.) processed by the Massachusetts Department of
Public Health Laboratory. The OMT specimens were
tested for HIV antibodies by enzyme-linked immunosorb-
ent assay (ELISA) and confirmed by western blot. Testing
for HCV was not conducted.
Exposure
The primary exposure of interest was age, dichoto-
mized as younger (<25 years) or older (≥ 25 years).
This definition of younger and older age was chosen a
priori to correspond to the upper age for which hepa-
titis rates increased in Massachusetts (15–24 years of
age) as described in the MMWR [1]. We also consid-
ered age as a categorical (18–25, >25-40, and >40 years)
and a continuous variable in Aim 2 to further explore
the association of age with sharing.
Outcome
The outcome for Aims 2 and 4 was any disclosure of
shared needles or other injection drug use equipment
within the past 30 days based on responses to the ques-
tion: “In the past 30 days when you injected drugs, how
often did you use shared needles or works?” Responses
varied from ‘never’, ‘sometimes’, ‘often’, and ‘always’. For
these analyses,‘any use’ was defined as a report of ‘some-
times’,‘often’,o r‘always’ sharing.
Covariates
We considered as potential confounders of the association
between age and sharing (Aim 2) several risk factors for
sharing identified in the literature, including: race; gender;
education level (less than high school or high school and
higher); current working status; living status (homeless,
staying in shelter, or living temporarily with friends or
family versus living in house, apartment, public housing,
rooming house, halfway house, or group home); frequency
of injection use in the past 30 days; specific drugs used
in the past 30 days (injected or otherwise) (heroin,
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inhalants, barbiturates, benzodiazepines, hallucinogens);
PTSD symptoms; history of receiving money in exchange
for sex; and whether US born (defined as born in the US
excluding Puerto Rico and other territories).
Event-level factors
For Aim 3, we compared the prevalence of factors present
during the most recent sharing episode (“event-level
factors”) for younger and older injectors. In particular,
we explored the type of drug shared, whether the individ-
ual had their own drugs to inject, the type of injection
partner, whether the individual experienced withdrawal
symptoms before injection, the setting of the sharing
event, and where the individual obtained the needles used
in the sharing event. These factors are important in defin-
ing the context of a recent sharing event; differences in
the prevalence of these factors by age can help elucidate
when and why younger and older individuals share.
Effect modifiers
We also had an a priori interest in examining a subset
of the covariates summarized above as potential effect
modifiers of the association between age and sharing
(Aim 4) because of their association with life stressors or
social instability: history of receiving money in exchange
for sex; PTSD symptoms; and whether US born.
HCV and HIV testing
Participants were also asked whether they had ever been
tested for HCV. If they answered ‘yes’, they were asked
whether they had received their test results, and if so,
whether the results were positive or negative. This infor-
mation, and the results of HIV testing, were summarized
for the group as a whole, both by age group and by sharing
status (Aim 5).
Statistical analysis
We summarized study sample characteristics, including
demographics, drug using practices, HCV testing history,
and HIV serostatus. We compared younger and older
injection drug users by these characteristics using chi-
square tests. Among those individuals who reported any
sharing, we compared factors present during the most
recent sharing event (event-level factors) for younger
versus older users using chi-square tests, to explore
differences in prevalence for younger versus older users
who shared.
We used logistic regression models to estimate the as-
sociation between age and sharing. A univariable model
with dichotomous age as the sole predictor was first
developed to provide an unadjusted odds ratio (OR) for
the association of age with sharing. A multivariable
model was then built to estimate the association of age
and sharing, adjusting for confounding factors. Each po-
tential confounder of the association between age and
sharing was entered into the univariable model one at a
time. When inclusion of a specific variable changed the
OR for the unadjusted association between age and
sharing by more than 10%, this variable was included in
the final multivariable model as a confounder. Univari-
able and multivariable models with (a) continuous and
(b) categorical age were also developed; the multivariable
models included the covariates identified as confounders
in the primary (dichotomous age) multivariable model.
To explore effect modification, we stratified multivari-
able models (which included covariates identified as con-
founders for Aim 2) of age and sharing by the categories
of each potential effect modifier (history of receiving
money in exchange for sex, PTSD symptoms, whether US
born) to determine whether the association between age
and sharing differed between these different categories.
(For instance, we examined whether the association be-
tween age and sharing was different for those with PTSD
symptoms and for those without symptoms). In those situ-
ations where there was qualitative evidence of effect modi-
fication (for example, no association observed in one
category of the effect modifier but a strong association ob-
served in another category), we created interaction terms
between age and the covariate and included this term in
the model to determine whether the interaction term was
statistically significant.
Results
One thousand thirty substance users were enrolled in the
intervention study. Four hundred eighty-nine individuals
(47.5%) reported having injected drugs within the past
30 days. Our analysis sample included the 484 injection-
drug-using individuals (99%) who provided information
on whether they had shared injection equipment within
the past 30 days. One hundred one of the 484 individuals
(20.9%) were <25 years of age (18.9-24.9 years), and 383
(79.1%) were ≥25 years of age (25.2-54.3 years).
Table 1 summarizes the demographic and behavioral
characteristics of the study sample, stratified by age.
Several factors differed by age. Fifty-one percent of
younger users were female compared with 33% of older
users (p<0.01). Eighty-seven percent of younger users
were white non-Hispanic compared with 53% of older
users (p< 0.01). Frequency of cocaine use also differed
by age, with twice as many older users reporting daily
cocaine use (21.0% versus 10.1%, p=0.01). The majority
reported both daily use of heroin and daily injection
drug use; these proportions did not differ by age.
One hundred ninety-eight of 484 (40.9%) injection
drug users reported having shared within the past 30 days.
This proportion differed by age: approximately 50% of
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of those ≥25 years (p=0.02).
The unadjusted OR for the association between youn-
ger age and sharing was 1.72 (95% confidence interval
[95% CI] =1.11, 2.68). In the final multivariable model,
younger injection drug users had twice the odds of sharing
of older users (95% CI=1.26, 3.19) (Table 2). Variables
that were included in the final model as confounders of
the association between age and sharing included fre-
quency of cocaine/crack use, injection frequency, and
whether US born. Those who reported using cocaine or
crack daily had 2.75 times the odds of sharing of those
who did not use cocaine or crack. Those who were born
outside the US had twice the odds of sharing of those born
in the US. Injection frequency was not associated with
sharing in the multivariable model. Gender, education
level, and homelessness did not confound the association
between age and sharing. The adjusted OR for continuous
age and sharing was 0.96 (95% CI= 0.94, 0.98). The ad-
justed OR for individuals >25-40 years (versus 18–25 years)
was 0.61 (95% CI=0.38, 0.99), and for individuals
older than 40 years (versus 18–25 years) was 0.29 (95%
CI=0.16, 0.53).
Table 3 summarizes the event-level factors present
during the most recent sharing event for the 198 indi-
viduals who reported sharing, stratified by age group. A
significantly lower proportion of younger than older in-
dividuals said that they had their own drugs available for
injection (50% versus 75%, p<0.001). Most individuals
(77%), regardless of age, reported using heroin during
their most recent sharing event, and the majority also
reported experiencing withdrawal symptoms prior to
injecting. A somewhat lower proportion of younger than
older users reported injecting either at their home or
that of a friend, but this difference was not statistically
significant. A higher proportion of younger than older
users reported being with a sexual partner (42% versus
27%), but overall the difference was not statistically signifi-
cant. Most individuals obtained their needles at either a
needle exchange or pharmacy.
Table 1 Characteristics of out-of-treatment injection drug
users, by age (N=484)
Characteristic Younger than 25
(N= 101) N (%)
25 or older
(N=383) N (%)
p-value
Female 52 (51.5) 125 (32.6) <0.01
Race <0.01
Black 1 (1.0) 54 (14.1)
White, non-Hispanic 88 (87.1) 204 (53.3)
Hispanic 11 (10.9) 120 (31.3)
Other 1 (1.0) 5 (1.3)
Born in US 95 (94.1) 332 (86.7) 0.04
Homeless 45 (44.6) 195 (50.9) 0.26
Education ≥High School 74 (73.3) 257 (67.1) 0.24
Currently Working 17 (16.8) 34 (8.9) 0.02
PTSD Symptoms
Score >50
59 (58.4) 211 (55.2) 0.57
Frequency of
Cocaine/Crack Use
0.01
No use 33 (33.3) 152 (39.9)
1-3 times per month 22 (22.2) 57 (15.0)
1-6 times per week 34 (34.4) 92 (24.1)
Daily 10 (10.1) 80 (21.0)
Frequency of
Heroin Use
0.60
No use 5 (5.2) 10 (2.6)
1-3 times per month 12 (12.5) 44 (11.6)
1-6 times per week 11 (11.5) 50 (13.2)
Daily 68 (70.8) 276 (72.6)
Frequency of Injection
Drug Use
0.86
1-3 times per month 15 (15.5) 56 (14.7)
1-6 times per week 14 (14.4) 48 (12.6)
Daily 68 (70.1) 277 (72.7)
History of Exchanging
Sex for Money
26 (25.7) 93 (26.5) 0.92
Any Needle Sharing,
past 30 days
52 (51.5) 146 (38.1) 0.02
The following variables had missing observations: PTSD symptoms (n =1); cocaine/
crack frequency (n=4); heroin frequency (n=8); injection frequency (n=6).
Table 2 Association between age and sharing of injection
drug equipment (N=484)
Characteristic Unadjusted
model
Multivariable
model
P-value
Age in years 0.004
<25 1.72 (1.11, 2.68) 1.99 (1.25, 3.18)
≥25 ref ref
Frequency of
Cocaine/Crack Use
0.002
Daily 2.75 (1.62, 4.68)
1-6 times per week 1.87 (0.90, 3.03)
1-3 times per month 1.61 (0.90, 2.85)
No use ref
Born outside US 2.09 (1.16, 3.79) 0.02
Frequency of Injection
Drug Use
0.24
Daily 1.59 (0.90, 2.82)
1-6 times per week 1.73 (0.82, 3.62)
1-3 times per month ref
Frequency of cocaine/crack use, born outside US, and injection frequency are
included in the multivariable model as confounders of the association
between age and injection equipment sharing.
Sharing is defined as any sharing of injection drug equipment in the past 30 days.
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tween categories of each potential effect modifier, includ-
ing PTSD positivity, receipt of money for sex, and whether
US born (Table 4). Specifically, among individuals with
a PTSD symptom score ≤50 (indicating fewer PTSD
symptoms), younger individuals had four times the odds
of sharing of older individuals, while among those with
a PTSD symptom score >50, there was no association
between age and sharing. Similarly, among those with
no history of receiving money for sex, younger individ-
uals had more than twice the odds of sharing of older
individuals, but no association was observed among
those with a history of receiving money for sex. For
those born in the US, there was a strong association
between younger age and sharing, but among those
born outside the US, there was no association between
age and sharing.
Among those without PTSD, 60% of younger and 30%
of older users shared (p<0.01), while among those with
PTSD, 45% of both age groups reported sharing (p=0.87).
Among those not reporting exchange of money for sex, a
significantly higher proportion of the younger injection
drug users reported sharing (55% versus 35% [p<0.01]);
but among those who said they had received money in ex-
change for sex, about 50% of both younger and older indi-
viduals reported sharing (p=0.58). We observed a similar
pattern for place of birth: among those born in the US,
younger individuals were more likely than older to report
sharing (54% versus 35%, p<0.01), while among those not
born in the US, there was greater reporting of sharing
among older users (61% versus 17%, p=0.04), although
the numbers in these cells were very small.
Overall, 77% of the study sample reported having been
tested for HCV, and there was no difference in testing
by age (p= 0.22). Most individuals (95%) received their
test results, again with no difference by age (p=0.30).
Among those who received their HCV test results, youn-
ger individuals were somewhat less likely to report having
tested positive (62% versus 71%), but this difference was
not statistically significant (p=0.33). There was also no
difference in HCV testing patterns between those who re-
ported current sharing and those who did not (p=0.66);
Table 3 Event-level characteristics at most recent drug
injection equipment sharing event (N= 198)
Event-level
characteristic
Younger than 25
(n=52) n (%)
25 or older
(n=146) n (%)
P-value
Had Own Drugs 26 (50.0) 109 (74.7) 0.001
Type of Drug Injected 0.50
Heroin 42 (80.8) 110 (75.3)
Cocaine 4 (7.7) 7 (4.8)
Heroin and Cocaine 6 (11.5) 28 (19.2)
Other 0 (0) 1 (0.7)
Injection Setting 0.20
Shooting Gallery 2 (3.9) 7 (4.8)
Home/Friend’s Home 21 (41.2) 80 (54.8)
Public Place 28 (54.9) 59 (40.4)
Injection Partner 0.22
Sexual Partner 22 (42.3) 40 (27.4)
Friends 19 (36.5) 74 (50.7)
Stranger(s) 2 (3.9) 7 (4.8)
Alone 9 (17.3) 25 (17.1)
Where Obtained
Needles
0.36
Needle Exchange 25 (49.0) 87 (60.0)
Injection Partner(s) 7 (13.7) 22 (16.2)
Pharmacy 18 (35.3) 35 (34.1)
Found 1 (2.0) 1 (0.7)
Withdrawal Symptoms
before Injection
40 (76.9) 111 (76.0) 0.90
Missing observations: Setting=1; Where Obtained Needles=2.
Table 4 Effect modification of the association between age and sharing of injection drug equipment
Age, yrs (n) % Share OR (95% CI) Age, yrs (n) % Share OR (95% CI) p-value for
interaction term
PTSD Symptoms Score ≤50 (n=213) PTSD Symptoms Score >50 (n= 270)
<25: n=42 59.5% 4.07 (1.89, 8.77) <25: n= 59 45.5% 1.29 (0.69, 2.39)
0.09
≥25: n= 171 30.4% ref ≥25: n=211 44.6% ref
No History of Money for Sex (n= 332) History of Money for Sex (n= 119)
<25: n=74 55.4% 2.67 (1.52, 4.66) <25: n= 26 42.3% 0.89 (0.34, 2.34)
0.05
≥25: n= 258 34.5% ref ≥25: n=93 48.4% ref
Born in US (n=427) Born outside US (n= 57)
<25: n=95 53.7% 2.37 (1.46, 3.86) <25: n= 51 16.7% 0.15 (0.01, 1.99)
<0.01
≥25: n= 332 34.6% ref ≥25: n=6 60.8% ref
N=33 missing information on receipt of money for sex.
Models are adjusted for frequency of cocaine injection, frequency of injection drug use, and (except for model of effect modification by US born) whether US born.
Sharing is defined as any sharing of injection drug equipment in the past 30 days.
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those who reported sharing injection equipment were sig-
nificantly more likely to report testing positive (80% versus
62%, p<0.01).
Ten percent of those 25 years and older, and 5% of those
younger than 25 years, tested positive for HIV (p=0.17).
The prevalence of HIV infection did not differ between
those reporting shared use of injection equipment and
those reporting no sharing (7.6% versus 10.5%, p=0.43).
Discussion
In this paper, we describe a cohort of injection drug
users whose primary drug of choice was heroin. The
demographic makeup of the cohort varied by age, with
individuals <25 years old more likely to be female and
white non-Hispanic. The cohort was comprised of individ-
uals with fairly severe substance use, with the majority
reporting daily injection use and daily heroin use. In
addition, most reported experiencing withdrawal symp-
toms prior to their most recent injection equipment
sharing event.
Injection drug use frequency did not vary by age; how-
ever, sharing of injection equipment did vary by age, with
individuals <25 years old significantly more likely to share
than individuals ≥25 years old. Our findings are consistent
with those of most previous studies that examined the
association between age and sharing. This association
remained strong after adjusting for several risk factors of
sharing including frequency of cocaine use, frequency of
injection, and whether US born. We did not have informa-
tion on age at initiation of injection drug use. However, it
is reasonable to propose that younger individuals in our
cohort on average initiated injection drug use more re-
cently than did older individuals. Since people are often
introduced to injection drug use by other users, one rea-
son for the association between younger age and sharing
may be that younger, newer users still rely on others’ help
when injecting [14]. Our finding that younger individuals
who share were more likely than older individuals to re-
port that they did not have their own drugs to inject is
consistent with this reason. Use and abuse of prescription
opioids is also high among young individuals and has
emerged as an important introduction to heroin use and
heroin injection [21]. It is believed to be one of the reasons
for the recent increase in injection drug use and HCV in-
fection in young adults observed in Massachusetts and
elsewhere [22].
While younger age was, overall, a strong risk factor for
sharing, we found this association differed qualitatively de-
pending on other factors that may be related to personal
stressors or social instability. To our knowledge, this is the
first study to have examined and identified potential effect
modifiers of the association between age and sharing.
Specifically, we found that the effect of younger age on
sharing was substantial and significant among individ-
uals who were born in the US, who did not have a his-
tory of receiving money for sex, or who did not have
symptoms of PTSD. However, among those with one or
more of these stressors, younger age was not associated
with sharing. While we emphasize that these effect
modification analyses and results are exploratory, they
do suggest that, in the presence of other destabilizing
factors in the lives of injection drug users, sharing is more
prevalent among all ages, and the relative importance of
younger age as a risk factor for sharing is diminished.
We found evidence that, in the presence of these
stressors, the prevalence and frequency of sharing by older
users was greater and more similar to that of younger
users, than in the absence of these stressors. Previous
research has found that older users or individuals with more
extensive injection drug use experience are less likely to
share than are younger users, either because they have
learned how to inject on their own or because they have
learned the health risks of sharing injection equipment
[23]. However, it could be that in the chronic presence of
stressors such as PTSD or exchange sex, individuals are
not able to develop the capacity to reduce their frequency
of sharing as they get older. It may also be that individuals
with these stressors have less stable or more frequently
changing social networks, something which has also been
associated with more risky drug using behavior [24,25].
Factors specific to the social networks or life stressors of
injection drug users may in part explain the conflicting
results of previous studies regarding age and injection
equipment sharing. For example in Stein et al. [5], where
age was not significantly associated with sharing, all study
participants met DSM-IV criteria for major depressive
disorder, dysthymia, or persistent substance-induced
mood disorder.
Our results revealed greater reporting of sharing by
those born outside of the US. Most of the individuals in
our cohort who were born outside of mainland US were
born in Puerto Rico. Zerden et al. [26] recently showed
that Puerto Ricans born and residing in Puerto Rico
were more likely to share needles than were Puerto
Ricans born in the US and residing in Massachusetts.
Previous research has found that young injection drug
users have lower rates of HCV testing than older users
[27]. We did not observe the same finding in our cohort.
This may be due to the fact that these individuals were
identified in a clinical setting with minimal financial bar-
riers to care, and may, therefore, have had more access to
health care and testing services than other populations of
injecting drug users.
It is worth commenting that syringe and needle ex-
change and legal access to over-the-counter purchases have
been successful public health strategies in Massachusetts;
however, in our study, the majority of individuals who
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cent sharing event was obtained at either needle exchange
or pharmacy, and most individuals who were tested for
HCV reported testing positive. Access to clean equipment
for these individuals has, therefore, not translated into
sufficient protection against HCV infection. Strategies
to address the precursors of sharing are critically needed.
Our study has several limitations related to the cross-
sectional nature of the analyses. The lower prevalence of
sharing observed for older users might not be due to safer
injecting practices, but may instead be due to an overall
reduction in substance use or in injection frequency over
time, thereby reducing the opportunity for sharing. How-
ever, in our cohort, the frequency of injection drug use as
w e l la st h ef r e q u e n c yo fh e r o i nu s e( t h ed r u gm o s ti n d i -
viduals reported injecting) did not differ for older and
younger users. Alternatively, the lower prevalence of
sharing could be due to a survivor effect, where older indi-
viduals with years of sharing injection drug equipment do
not survive and are not represented in our cohort. We are
not able to assess this likelihood in the present study.
We did not have information on age at initiation of
injection drug use and, therefore, cannot confirm that
younger users initiated injection drug use more recently
than older users. We did not collect information on the
social networks of our participants; the potential influence
of social networks on the association between age and
sharing should be specifically assessed in future investiga-
tions. Our examination of effect modification was explora-
tory, as the study was not designed to examine effect
modification and was, therefore, not optimally powered to
identify statistically significant modifiers. Future studies
with larger study samples should examine the same and
additional effect modifiers related to social stress and
instability, such as stressful life events and social support.
Also, since our cohort was comprised of injection drug
users registered for health care at a busy urban emergency
department, they are not necessarily representative of all
injection drug users in Massachusetts. We did not con-
duct HCV testing and instead relied on self-reported in-
formation on HCV testing practices, which may mean
that the observed prevalence of HCV testing was subject
to recall bias. However, we did conduct HIV testing, and
HIV test results were highly consistent with individuals’
self-reports of their HIV serostatus, suggesting that biased
reporting of HCV testing patterns was minimal (data not
shown).
Conclusions
Most of the individuals in our cohort, regardless of age,
reported daily heroin use and daily drug injection. Many
of the individuals, again regardless of age, reported
symptoms of PTSD, were homeless, or were not cur-
rently working, and older individuals reporting these
stressors were more likely to share. Therefore, our find-
ings suggest that harm-reduction efforts for these indi-
viduals should incorporate not just efforts to reduce
drug injection and sharing of drug equipment, but also
should address larger disruptive aspects of these individ-
uals’ lives—such as mental health and social instability. In
addition, as other investigations have pointed out, preven-
tion and harm-reduction efforts for younger individuals
who have just begun to inject should continue to ensure
that these individuals are knowledgeable regarding the
risks of sharing [28,29].
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